Beta Drugs Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Beta Drugs Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹87Over the last 3 years, every ₹100 of reported profit came with ₹87 of operating cash.
Lower than 65% of Healthcare companies in India.
Self-Funding Ratio
1.0×Over the last 3 years its own operating cash covered its investment spending (capex) 1.0 times.
Lower than 64% of Healthcare companies in India.
Cash Locked Ratio
₹28For every ₹100 of sales, ₹28 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹21 tied up three years earlier.
More money tied up than 57% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹7Sales grew 69% in 3 years; of every extra ₹100 of sales, ₹7 became extra profit.
Lower than 76% of Healthcare companies in India.
Asset Productivity Ratio
+69% / +150%In 3 years sales changed by +69% while total assets changed by +150%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
2.6×Debt due within a year is covered 2.6 times by its yearly operating cash.
Higher than 63% of Healthcare companies in India.
Cash Cushion Ratio
−1%Debt, after subtracting cash, equals 1% of its market value (net debt).
Lower than 51% of Healthcare companies in India.
Tangible Assets Ratio
98%Of every ₹100 the company owns, ₹98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 53% of Healthcare companies in India.
Tangible Net Worth Ratio
96%Of every ₹100 of net worth, ₹96 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 51% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Beta Drugs Limited owes ₹0.51 for every ₹1 it owns. Net profit fell 2% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
29.0Investors pay ₹29.0 for every ₹1 of Beta Drugs Limited's yearly profit, lower than 66% of Healthcare companies in India.
P/B ratio
8.16The share price is 8.16 times Beta Drugs Limited's book value per share, higher than 78% of Healthcare companies in India.
Market cap
₹1,998 CrThe total market value of all of Beta Drugs Limited's shares at today's price (share price × number of shares), smaller than 67% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹245 CrWhat Beta Drugs Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹241.47Net worth divided by the number of shares. The share price of ₹1,971 is 8.2 times this, which is the P/B above.
Return on equity (ROE)
28.1%Beta Drugs Limited earned 28.1% on its shareholders' money over the last year, higher than 92% of Healthcare companies in India.
Owes vs Owns
0.51×Beta Drugs Limited owes ₹0.51 for every ₹1 it owns (moderate), higher than 85% of Healthcare companies in India.
Dividend yield
NoneBeta Drugs Limited does not currently pay a dividend.
Revenue growth
+6%Revenue rose 6% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Profit growth
-2%Net profit fell 2% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Profit margin
10.8%Beta Drugs Limited keeps ₹11 of every ₹100 of revenue as net profit.
Cash quality
0.9×Cash from Beta Drugs Limited's business was 0.9× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
3.9×Beta Drugs Limited's operating profit covered its interest costs 3.9 times in the year to Mar 2026.
Cash vs debt
Net debtBeta Drugs Limited had ₹23 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Beta Drugs Limited's P/E ratio?
Investors pay ₹29.0 for every ₹1 of Beta Drugs Limited's yearly profit, lower than 66% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Beta Drugs Limited: ₹1,998 Cr ÷ ₹245 Cr (31 Mar 2026) = 8.2.
What is Beta Drugs Limited's return on equity?
Beta Drugs Limited earned 28.1% on its shareholders' money over the last year, higher than 92% of Healthcare companies in India.
How much does Beta Drugs Limited owe compared with what it owns?
Beta Drugs Limited owes ₹0.51 for every ₹1 it owns (moderate), higher than 85% of Healthcare companies in India.
Does Beta Drugs Limited pay a dividend?
No. Beta Drugs Limited does not currently pay a dividend.
Is Beta Drugs Limited's revenue growing?
Revenue rose 6% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.